DiagnoCure Posts Sharp Q3 Revenue Increase; Warns It May Not Receive Payment for Services Rendered | GenomeWeb

NEW YORK (GenomeWeb News) – DiagnoCure's fiscal third-quarter revenues increased 143 percent year over year, the Quebec City-based cancer diagnostic firm reported after the close of the market on Thursday.

For the three months ended July 31, revenues totaled C$709,754 (US$722,057), compared to C$292,073 a year ago. Revenues from royalty payments slipped to C$142,102 from C$168,273 a year ago as revenues from Gen-Probe, now part of Hologic, decreased to C$136,843 from C$155,024 a year ago as austerity measures in Europe resulted in softness the region, DiagnoCure said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.